â??Development of new formulation of Bacopa monniera to improve its penetration into the brainâ??

DEVELOPMENT OF NEW FORMULATION OF BACOPA MONNIERA TO IMPROVE ITS PHARMACOKINETIC PROPERTIES

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/02/003414

Enrollment

Registered

2013-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: intervention by using new formulation of bacopa monniera: Comparing oral tablet formulation with new oral formulation of bacopa monniera to the healthy human volunteers and efficacy as

Eligibility

Inclusion criteria

Inclusion criteria: Healthy volunteers

Exclusion criteria

Exclusion criteria: Severally ill patient, heart failure, kidney failure patient. Pregnant,lactating mothers. Pediatric, geriatric age group. Any concomitant disease.

Design outcomes

Primary

Measure	Time frame
Primary: To formulate a new formulation of Bacopa monniera (Sanskrit & Hindi vernacular: Brahmi) to improve its pharmacokinetic properties. To obtain kinetic data for the new formulationTimepoint: one year	—

Secondary

Measure	Time frame
To study ADRs and AEs, if anyTimepoint: One year	—

Countries

India

Contacts

Public ContactDr Vijay Thawani

VCSGGIMSR

vijaythawani@rediffmail.com7579039260

Outcome results